Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors

International Journal of Cancer

Volumn 131, Issue 10, 2012, Pages 2433-2444

  Sultana, Rebeka ^a   McNeill, Daniel R ^b   Abbotts, Rachel ^a   Mohammed, Mohammed Z ^a   Zdzienicka, Malgorzata Z ^c   Qutob, Haitham ^a   Seedhouse, Claire ^a   Laughton, Charles A ^d   Fischer, Peter M ^d   Patel, Poulam M ^a   Wilson III, David M ^b   Madhusudan, Srinivasan ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

apyrimidinic endonuclease 1 (APE1); base excision repair (BER); BRCA deficiency; DNA repair; human apurinic; small molecule inhibitors; synthetic lethal targeting

Indexed keywords

2 [(4,5 DIMETHOXY 2 METHYL 3,6 DIOXO 1,4 CYCLOHEXADIEN 1 YL)METHYLENE]UNDECANOIC ACID; ATM PROTEIN; ATM PROTEIN INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; DEOXYRIBONUCLEASE; DNA (APURINIC OR APYRIMIDINIC SITE) ENDONUCLEASE 1; DNA (APURINIC OR APYRIMIDINIC SITE) ENDONUCLEASE INHIBITOR; ESTERASE INHIBITOR; METHOXYAMINE; MYRICETIN; N (4 FLUOROPHENYL) 2 [4 PHENYLSULFONYL 2 (4 TOLYL)OXAZOL 5 YL]SULFANYL ACETAMIDE; N (9,10 DIOXO 1 ANTHRYL) 2 (1H 1,2,4 TRIAZOL 5 YLSULFANYL)ACETAMIDE; PROTEIN INHIBITOR; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL LINE; CELL STRAIN CAPAN 1; CELL STRAIN E8; CELL STRAIN HELA SILENCIX; CELL STRAIN MCF 7; CELL STRAIN MDA MB 436; CELL STRAIN PANC1; CELL STRAIN V C8; CELL STRAIN V C8 (REV1); CELL STRAIN V E5; CELL STRAIN V79; CHO CELL; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; EXCISION REPAIR; G2 PHASE CELL CYCLE CHECKPOINT; GENETIC PARAMETERS; HELA CELL; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNTHETIC LETHALITY; WILD TYPE;

ANIMALS; BRCA1 PROTEIN; BRCA2 PROTEIN; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CRICETINAE; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; ENZYME INHIBITORS; HUMANS;

EID: 84867082212     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27512     Document Type: Article

References (44)

1. Abbotts R, Madhusudan S,. Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer. Cancer Treat Rev 2010; 36: 425-35.
2. Wilson DM, 3rd, Bohr VA,. The mechanics of base excision repair, and its relationship to aging and disease. DNA repair 2007; 6: 544-59.
3. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T,. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913-7.
4. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-21.
5. Lord CJ, Ashworth A,. Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol 2008; 8: 363-9.
6. Chen S, Parmigiani G,. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25: 1329-33.
7. Helleday T,. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol 2011; 5: 387-93.
8. Annunziata CM, O'Shaughnessy J,. Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer. Clin Cancer Res 2010; 16: 4517-26.
9. Lindahl T, Nyberg B,. Rate of depurination of native deoxyribonucleic acid. Biochemistry 1972; 11: 3610-8.
10. Lindahl T, Karlstrom O,. Heat-induced depyrimidination of deoxyribonucleic acid in neutral solution. Biochemistry 1973; 12: 5151-4.
11. Lindahl T,. Instability and decay of the primary structure of DNA. Nature 1993; 362: 709-15.
12. Demple B, Harrison L,. Repair of oxidative damage to DNA: enzymology and biology. Ann Rev Biochem 1994; 63: 915-48.
13. Hickson ID,. Base excision repair of DNA damaged. Landes Bioscience, 1997.
14. Wilson DM, 3rd, Barsky D,. The major human abasic endonuclease: formation, consequences and repair of abasic lesions in DNA. Mutat Res 2001; 485: 283-307.
15. Liu L, Gerson SL,. Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway. Curr Opin Investig Drugs 2004; 5: 623-7.
16. Kingma PS, Osheroff N,. The response of eukaryotic topoisomerases to DNA damage. Biochim Biophys Acta 1998; 1400: 223-32.
17. Pourquier P, Ueng LM, Kohlhagen G, Mazumder A, Gupta M, Kohn KW, Pommier Y,. Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I. J Biol Chem 1997; 272: 7792-6.
18. Ma W, Westmoreland JW, Gordenin DA, Resnick MA,. Alkylation base damage is converted into repairable double-strand breaks and complex intermediates in G2 cells lacking AP endonuclease. PLoS Genet 2011; 7: e1002059.
19. Bhakat KK, Izumi T, Yang SH, Hazra TK, Mitra S,. Role of acetylated human AP-endonuclease (APE1/Ref-1) in regulation of the parathyroid hormone gene. Embo J 2003; 22: 6299-309.
20. Berquist BR, McNeill DR, Wilson DM, 3rd,. Characterization of abasic endonuclease activity of human Ape1 on alternative substrates, as well as effects of ATP and sequence context on AP site incision. J Mol Biol 2008; 379: 17-27.
21. Madhusudan S, Smart F, Shrimpton P, Parsons JL, Gardiner L, Houlbrook S, Talbot DC, Hammonds T, Freemont PA, Sternberg MJ, Dianov GL, Hickson ID,. Isolation of a small molecule inhibitor of DNA base excision repair. Nucleic acids Res 2005; 33: 4711-24.
22. Mohammed MZ, Vyjayanti VN, Laughton CA, Dekker LV, Fischer PM, Wilson DM, 3rd, Abbotts R, Shah S, Patel PM, Hickson ID, Madhusudan S,. Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines. Br J Cancer 2011; 104: 653-63.
23. Simeonov A, Kulkarni A, Dorjsuren D, Jadhav A, Shen M, McNeill DR, Austin CP, Wilson DM, 3rd,. Identification and characterization of inhibitors of human apurinic/apyrimidinic endonuclease APE1. PLoS One 2009; 4: e5740.
24. Wilson DM, 3rd, Simeonov A,. Small molecule inhibitors of DNA repair nuclease activities of APE1. Cell Mol Life Sci 2010; 67: 3621-31.
25. Seiple LA, Cardellina JH, 2nd, Akee R, Stivers JT,. Potent inhibition of human apurinic/apyrimidinic endonuclease 1 by arylstibonic acids. Mol Pharmacol 2008; 73: 669-77.
26. Zawahir Z, Dayam R, Deng J, Pereira C, Neamati N,. Pharmacophore guided discovery of small-molecule human apurinic/apyrimidinic endonuclease 1 inhibitors. J Med Chem 2009; 52: 20-32.
27. Bapat A, Glass LS, Luo M, Fishel ML, Long EC, Georgiadis MM, Kelley MR,. Novel small-molecule inhibitor of apurinic/apyrimidinic endonuclease 1 blocks proliferation and reduces viability of glioblastoma cells. J Pharmacol Exp Ther 2010; 334: 988-98.
28. Wiegant WW, Overmeer RM, Godthelp BC, van Buul PP, Zdzienicka MZ,. Chinese hamster cell mutant, V-C8, a model for analysis of Brca2 function. Mutat Res 2006; 600: 79-88.
29. Zdzienicka MZ, Jaspers NG, van der Schans GP, Natarajan AT, Simons JW,. Ataxia-telangiectasia-like Chinese hamster V79 cell mutants with radioresistant DNA synthesis, chromosomal instability, and normal DNA strand break repair. Cancer Res 1989; 49: 1481-5.
30. McNeill DR, Wilson DM, 3rd,. A dominant-negative form of the major human abasic endonuclease enhances cellular sensitivity to laboratory and clinical DNA-damaging agents. Mol Cancer Res 2007; 5: 61-70.
31. Seedhouse CH, Hunter HM, Lloyd-Lewis B, Massip AM, Pallis M, Carter GI, Grundy M, Shang S, Russell NH,. DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412. Leukemia 2006; 20: 2130-6.
32. Fishel ML, Jiang Y, Rajeshkumar NV, Scandura G, Sinn AL, He Y, Shen C, Jones DR, Pollok K, Ivan M, Maitra A, Kelley MR,. Impact of APE1/Ref-1 redox inhibition on pancreatic tumor growth. Mol Cancer Ther 2011; 10: 1698-708.
33. Ohnishi T, Mori E, Takahashi A,. DNA double-strand breaks: their production, recognition, and repair in eukaryotes. Mutat Res 2009; 669: 8-12.
34. Robson CN, Hickson ID,. Isolation of cDNA clones encoding a human apurinic/apyrimidinic endonuclease that corrects DNA repair and mutagenesis defects in E. coli xth (exonuclease III) mutants. Nucleic Acids Res 1991; 19: 5519-23.
35. Demple B, Herman T, Chen DS,. Cloning and expression of APE, the cDNA encoding the major human apurinic endonuclease: definition of a family of DNA repair enzymes. Proc Natl Acad Sci USA 1991; 88: 11450-4.
36. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG,. PARP inhibition: PARP1 and beyond. Nature Rev 2010; 10: 293-301.
37. Mangerich A, Burkle A,. How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation. Int J Cancer 2011; 128: 251-65.
38. Underhill C, Toulmonde M, Bonnefoi H,. A review of PARP inhibitors: from bench to bedside. Ann Oncol 2011; 22: 268-79.
39. Yap TA, Sandhu SK, Carden CP, de Bono JS,. Poly(ADP-ribose) polymerase (PARP) inhibitors: exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin 2011; 61: 31-49.
40. Carden CP, Yap TA, Kaye SB,. PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers. Curr Opin Oncol 2010; 22: 473-80.
41. Seo Y, Kinsella TJ,. Essential role of DNA base excision repair on survival in an acidic tumor microenvironment. Cancer Res 2009; 69: 7285-93.
42. Bindra RS, Gibson SL, Meng A, Westermark U, Jasin M, Pierce AJ, Bristow RG, Classon MK, Glazer PM,. Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res 2005; 65: 11597-604.
43. Bindra RS, Glazer PM,. Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia. Oncogene 2007; 26: 2048-57.
44. Bindra RS, Schaffer PJ, Meng A, Woo J, Maseide K, Roth ME, Lizardi P, Hedley DW, Bristow RG, Glazer PM,. Alterations in DNA repair gene expression under hypoxia: elucidating the mechanisms of hypoxia-induced genetic instability. Ann N Y Acad Sci 2005; 1059: 184-95.